Toronto, Ontario – February 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®), a developer of advanced Photo Dynamic Therapy (“PDT”), for serious and life-threatening diseases, announced today that research on its Anti-Cancer Technology (“ACT”) platform involving its lead Photo Dynamic Compound (“PDC”) TLD-1433 has shown that it has significantly less skin toxicity than the Food and Drug Administration (“FDA”) approved PDC Photofrin®. Photofrin® has been documented to induce skin sensitivity in patient’s treated with the PDC to sunlight or bright lights after administration. Patients who receive Photofrin® will be photosensitive and must strictly avoid exposure of skin and eyes to direct sunlight or bright indoor light (i.e.: examination lamps, dental lamps, operating room lamps, unshaded light bulbs at close proximity, etc.) for at least 30 days post treatment. Some patients may remain photosensitive for up to 90 days or more. The photosensitivity is due to residual traces of the drug, which … Read More

Toronto, Ontario – February 11, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has been ranked in the Toronto Stock Exchange Venture (“TSXV”) 50®. Every year, the TSX Venture 50® ranks the strongest companies on the TSXV by share price, trading volume, market capitalization and analyst coverage. The winning companies have seen impressive growth over the past year, offered strong return to their shareholders and are actively traded in the market. The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors – mining, oil & gas, technology & life sciences, diversified industries and clean technology – based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2014. The ranking is being announced today with the … Read More

Toronto, Ontario – February 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has successfully completed the design of the next generation therapeutic laser, the TLC-2000, and has filed for Health Canada approval via a Class 3 Medical Device Licence application. According to Health Canada guidelines, approval of a Class 3 Medical Device Licence is expected within approximately 75 days, which would indicate final approval on or about April 2015. Food and Drug Administration (“FDA”) and Conformité Européene (”CE”) approval of the TLC-2000 will be submitted in March 2015 and is expected on or about June 2015. The Theralase TLC-2000 is a next generation patented biofeedback therapeutic laser system that the Company has researched and systematically developed over the last 12 years, commencing with the issue of US patent 6,413,267 on July 2, 2002. Between 2003 to 2009, extensive scientific research of the laser biofeedback … Read More

Toronto, Ontario, February 3, 2015 /Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)), a developer of advanced Photo Dynamic Therapy (“PDT“), for serious and life-threatening diseases, announced today that research on its Anti-Cancer Technology (“ACT“) platform involving its lead Photo Dynamic Compound (“PDC“) TLD-1433 has been peer reviewed and accepted for publication in the journal Photochemical & Photobiological Sciences. Results from the preclinical studies of Theralase’s PDT entitled, “A novel class of ruthenium-based photosensitizers effectively kills in-vitro cancer cells and in-vivo tumors” has been accepted for publication by the journal of Photochemical & Photobiological Sciences, a society-owned journal publishing high quality research on all aspects of photochemistry and photobiology. Preclinical research demonstrated that Theralase’s lead drug candidate TLD-1433 for advanced PDT: -Effectively destroyed cancer cells and tumors -Provided a clinically significant delay in tumor growth -Increased tumor-free survival in a model of colorectal cancer The research conducted by Dr. Lothar Lilge, a … Read More

Toronto, Ontario, January 29, 2015 / Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that its latest research on its lead Photo Dynamic Compound (“PDC“) TLD-1433 binding to transferrin has been accepted for presentation at the 15th International Photodynamic Association (“IPA“) / Society of Photo-Optical Instrumentation Engineers (“SPIE“) Biophotonics Conference taking place in Rio de Janeiro, Brazil from May 22 to 26, 2015. The IPA was founded in 1986. Its membership consists of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT“) and Photo Diagnosis (“PD“). The purpose of the IPA is promote the study of diagnosis and treatment using light and PDCs, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an International Congress every two years, which is a unique opportunity to sum up research activities in the … Read More

Toronto, Ontario – January 20, 2015, Theralase Technologies Inc. (“Theralase”)(TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has filed a provisional US patent application for “Transferrin Enhanced Photo Dynamic Therapy (“PDT”) Cancer Destruction” significantly increasing the targeting of its PDT technology; hence, also the efficacy and safety of the treatment.” Transferrin is a substance that naturally occurs in the body (iron-binding blood plasma glycoprotein) that controls the level of free iron in our biological fluids. When transferrin encounters a transferrin receptor (“TfR”) on the surface of a cell, it is able to more effectively bind to that specific cell and delivery its payload, in this case Theralase’s lead Photo Dynamic Compound (“PDC”), TLD-1433. Overexpression of transferrin receptors for a variety of cancers has been scientifically documented and is attributed to the malignant transformation of normal cells into cancer cells. Theralase’s recent scientific research, which is the subject of this particular  … Read More

Toronto, Ontario – January 15, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has identified its lead Photo Dynamic Compound (“PDC”) that it plans to enter into a Health Canada Clinical Trial Application (“CTA”) / Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) Application for the destruction of Non Muscle Invasive Bladder Cancer (“NMIBC”) in 2015. The lead PDC has been identified to be TLD-1433, a Ruthenium based PDC that has demonstrated a high Therapeutic Ratio, which has the highest overall performance in the green and red laser light spectrums for multiple cancer cell lines, including glioma (primary brain tumours that originate from the supportive cells of the brain) and bladder cancer. The Therapeutic Ratio represents the ability of the PDC to destroy cancer cells by comparing cancer cell destruction in the absence of light (dark toxicity) to cancer cell destruction when light activated … Read More

Toronto, Ontario – January 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that Roger Dumoulin-White, President and CEO of Theralase will present at the 2nd Annual AlphaNorth Capital Conference to be held at the Atlantis Resort on Paradise Island, Bahamas from January 16th to 18th, 2015. The 2nd Annual AlphaNorth Capital Conference in the Bahamas will feature some of the best small cap innovators in the technology, biotech, healthcare and special situations spaces and connect them with the top institutions and specialist brokers in North America through a full day series of one-on-one meetings between issuers and finance. Roger Dumoulin-White, President and CEO of Theralase stated that, “In 2015, one of Theralase’s key objectives is to introduce the Theralase story to new Canadian, US and international investors to allow them the opportunity to hear firsthand of our successes to date and the compelling reasons why investment … Read More

Toronto, Ontario – January 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today a summary of its 2014 scientific achievements published in peer reviewed, high impact scientific journals or presented at international conferences that detail its ongoing commitment to establishing the scientific and preclinical research required to support the launch of its cutting-edge technologies. In addition, Theralase confirms its 2015 strategic objectives with anticipated timing. From December 2013 to December 2014, the following peer reviewed papers have been published in high impact scientific journals or presented at international conferences and been globally recognized by the international scientific and medical community:   Photodynamic Inactivation of Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus with Ru(II)-based Type I/ Type II Photosensitizers (Photodiagnosis Photodynamic Therapy, 10(4):615-25, Dec. 2013) Theralase’s ability to destroy two types of bacteria (Staphylococcus aureus and Methicillin Resistant Staphylococcus aureus (MRSA)) up to 99.99999%, with a new class of … Read More

Toronto, Ontario – December 23, 2014, Theralase Technologies Inc. (“Theralase”)(TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has obtained preliminary results from the use of Photo Dynamic Therapy (“PDT”) to destroy bladder cancer in an orthotopic (“occurring at the normal place in the body”) rat model. The University of Toledo in conjunction with the Princess Margaret Cancer Centre, University Health Network (“UHN”) and Theralase conducted the experiment in a well-established orthotopic model for bladder cancer in rats. Experiment: The rat bladder urothelium (inner lining) sustained localized injury via cauterization to allow adhesion of AY27 rat bladder cancer cells One of the lead Theralase Photo Dynamic Compounds (“PDCs”) (TLD1433) was infused into the bladder once the tumour had reached 1 mm by 1 mm in size (Dose equal to 1 mg of PDC / 20 ml of distilled water solution) After 60 minutes incubation, the PDC was removed from the bladder … Read More